Evidence map›Paper›PMID 41142653›Full record

ArticleJGH open : an open access journal of gastroenterology and hepatology2025

A Clinical Prediction Model for Early Colectomy in Patients With Severe Ulcerative Colitis Treated With Tacrolimus.

Hikaru Shimizu, Kazuki Kakimoto, Mai Utsumi, Suzune Sugishima, Hideaki Mitooka, Noboru Mizuta, Ryosuke Yamaguchi, Masatoshi Kaizuka, Koji Nishida, Keijiro Numa and 7 more

Abstract read
In one paragraph

Article in JGH open : an open access journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hikaru Shimizu2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.
Kazuki Kakimoto2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.ORCID https://orcid.org/0000-0003-0564-2793
Mai Utsumi2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.
Suzune Sugishima2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.
Hideaki Mitooka2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.
Noboru Mizuta2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.
Ryosuke Yamaguchi2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.
Masatoshi Kaizuka2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.
Koji Nishida2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.
Keijiro Numa2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.ORCID https://orcid.org/0009-0003-6081-5287
Naohiko Kinoshita2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.
Kei Nakazawa2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.
Ryoji Koshiba2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.ORCID https://orcid.org/0009-0003-6607-0589
Yuki Hirata2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.ORCID https://orcid.org/0000-0002-3686-4690
Takako Miyazaki2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.
Shiro Nakamura2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.
Hiroki Nishikawa2nd Department of Internal Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.ORCID https://orcid.org/0009-0009-0488-3297

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aims: Tacrolimus is an effective treatment option for refractory ulcerative colitis; however, some patients still require colectomy due to insufficient response. Early assessment of surgical risk is clinically important, as delayed decision-making may worsen the patient's condition and increase the risk of postoperative complications. This study aimed to identify predictors of colectomy within 3 months of initiating tacrolimus therapy and to develop a clinically applicable prediction model. Methods: We conducted a retrospective analysis of hospitalized patients with severe ulcerative colitis treated with tacrolimus between 2011 and 2025. Fourteen clinical background variables were evaluated using LASSO-penalized logistic regression with cross-validation to construct the prediction model. Results: Among 114 patients, 24 (21.1%) underwent colectomy, including 16 (14.0%) within 3 months of treatment initiation. The LASSO regression identified three predictive variables: serum albumin level, hemoglobin level, and age at tacrolimus initiation. The resulting model demonstrated good discriminative performance, with an area under the curve of 0.78. Using a cutoff value of logit( Conclusion: We developed a clinical prediction model that accurately estimates the risk of early colectomy based on baseline clinical factors at the start of tacrolimus therapy. This model may serve as a practical tool to guide decision-making regarding surgical timing and overall treatment strategy.

Indexed as

colectomyprediction modeltacrolimusulcerative colitis

Identifiers

PMID41142653
PMCPMC12552740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.